IP Library › Granted Patent US 9,624,468
Granted Patent B2
US 9,624,468 · App. 14/398,664 · Granted Apr 18, 2017

Methods for generating the inner ear and other cranial placode-derived tissues using pluripotent stem cells

Inventors: Eri Hashino (Indianapolis, IN); Gerry Oxford (Indianapolis, IN); Karl R. Koehler (Indianapolis, IN)
Assignee: Indiana University Research & Technology Corporation
C12N5/0627C12N5/062G01N33/5044G01N33/5073C12N2501/113C12N2501/115C12N2501/15C12N2501/155C12N2501/415C12N2501/727C12N2506/02C12N2506/03C12N2533/90
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,624,468
App. No.
14/398,664
Granted
Apr 18, 2017
Kind
B2
Abstract

Disclosed herein are methods and compositions for generating cultures and isolated cell populations containing preplacodal ectoderms cells, otic placode cells, and inner ear sensory hair cells derived from pluripotent cells by modulating TGFβ, BMP, and FGF signaling pathways under defined culture conditions. Also described are methods for obtaining non-otic placodal tissues from pluripotent stem cells. Methods for identifying agents that induce or enhance differentiation and generation of hair cells are also disclosed. Methods for identifying cytoprotective agents for hair cells are also described.

Claims (5)

1. A method for producing preplacodal ectoderm cells, the method comprising the steps of: (i) culturing pluripotent stem cells selected from the group consisting of human pluripotent stem cells and mouse pluripotent stem cells for between 1 to 2 days under conditions that result in formation of embryoid bodies from the cultured pluripotent stem cells; (ii) adding one of (1) a gelatinous protein mixture secreted by Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells or (2) an effective amount of laminin and entactin, wherein the effective amount facilitates the formation of a basement membrane, to the cultured embryoid bodies formed in step (i); and (iii) culturing the embryoid bodies of step (ii) for about 2 days to about 3 days in the presence of BMP2, BMP4, or BMP7 and a TGF-β inhibitor to form non-neural ectoderm cells; and (iv) culturing the non-neural ectoderm cells formed in (iii) for about 3 days to about 5 days in the absence of the BMP2, BMP4, or BMP7 and the TGF-β inhibitor, and in the presence of an exogenous FGF and a BMP inhibitor, in floating culture for about 4 days to about 6 days after initiation of step (i), to generate a cell population comprising human or mouse preplacodal ectoderm cells, wherein said human preplacodal ectoderm cells express one or more of SIX1/4, EYA1/2, IRX1/2/3, AP2, DLX3/5/6, GATA2/3, FOXI1/3 and E-cadherin or wherein said mouse preplacodal ectoderm cells express at least one of Dlx3, Dlx5, Pax2, Pax8 and Eya1.

2. The method of claim 1 , wherein step (iii) comprises culturing the embryoid bodies in the presence of BMP4.

3. The method of claim 1 , wherein the pluripotent stem cells are human pluripotent stem cells.

4. The method of claim 3 , wherein the BMP2, BMP4, or BMP7, and the TGFβ inhibitor are added to the embryoid bodies formed in step (i) on day 5, 6, or 7.

5. The method of claim 1 , wherein the gelatinous protein mixture secreted by Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells or an effective amount of laminin and entactin is added to the cultured embryoid bodies on day 1.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2015
From: HASHINO, ERI; KOEHLER, KARL R.; OXFORD, GERRY
To: INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION
Reel/Frame 035478/0040 →
Continuity (3)
Provisional Application 61642701 · May 4, 2012
Provisional Application 61791567 · Mar 15, 2013
Related Publication 20150125953A1 · May 7, 2015